EP 1418936 A2 20040519 - PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING TH1 AND TH2 CELL RELATED DISEASES BY MODULATING THE TH1/TH2 RATIO.
Title (en)
PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING TH1 AND TH2 CELL RELATED DISEASES BY MODULATING THE TH1/TH2 RATIO.
Title (de)
PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR PROPHYLAXE ODER BEHANDLUNG VON TH1- UND TH2-ZELLE VERWANDTEN ERKRANKUNGEN, DURCH MODULIERUNG DES TH1/TH2 VERHÄLTNISSES
Title (fr)
COMPOSITIONS PHARMACEUTIQUES DESTINES A PREVENIR OU TRAITER LES MALADIES ASSOCIEES AUX CELLULES TH1 ET TH2 PAR MODULATION DU RAPPORT TH1/TH2
Publication
Application
Priority
- DK 0200295 W 20020507
- DK PA200100726 A 20010509
- US 28971101 P 20010509
Abstract (en)
[origin: WO02089832A2] Pharmaceutical composition for preventing or treating a Th1 cell- or Th2-cell-related disease in a human or an animal by modulating the Th1/Th2 ratio comprising an active substance consisting of (i) IL-4 and SDF-1 alpha , or IL-2 and SDF-1 alpha , respectively, as well as modulators thereof, (ii) an IL-4 stimulating adjuvant and SDF-1 alpha , or an IL-2 stimulating adjuvant and SDF-1 alpha , respectively, (iii) a modulator of the tyrosine kinases Syk or ZAP-70, or (iv) a modulator of the nuclear factors of activated T cells NFAT1 or NFAT2.
IPC 1-7
A61K 38/20; A61K 39/395; A61K 31/7125; A61K 38/45; A61K 38/17; A61K 31/00; C12N 15/11; C12Q 1/68; G01N 33/50; C12N 5/00; A61P 37/00; A61P 35/00
IPC 8 full level
A61K 31/00 (2006.01); A61K 31/7088 (2006.01); A61K 31/7125 (2006.01); A61K 33/06 (2006.01); A61K 33/24 (2019.01); A61K 33/40 (2006.01); A61K 33/42 (2006.01); A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 39/35 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61K 45/00 (2006.01); A61K 48/00 (2006.01); A61P 31/04 (2006.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01); A61P 37/06 (2006.01); A61P 43/00 (2006.01); C12N 5/0783 (2010.01); C12Q 1/48 (2006.01); G01N 33/50 (2006.01)
CPC (source: EP US)
A61K 31/00 (2013.01 - EP); A61K 31/7125 (2013.01 - EP); A61K 33/06 (2013.01 - EP); A61K 33/24 (2013.01 - EP US); A61K 33/42 (2013.01 - EP); A61K 38/1709 (2013.01 - EP); A61K 38/1793 (2013.01 - EP); A61K 38/195 (2013.01 - EP); A61K 38/2013 (2013.01 - EP); A61K 38/2026 (2013.01 - EP); A61K 38/45 (2013.01 - EP); A61K 39/39 (2013.01 - EP); A61P 31/00 (2018.01 - EP); A61P 31/04 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 37/00 (2018.01 - EP); A61P 37/06 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C12N 5/0636 (2013.01 - EP US); C12Q 1/485 (2013.01 - EP); G01N 33/505 (2013.01 - EP); A61K 2039/5158 (2013.01 - EP US); A61K 2039/55516 (2013.01 - EP); A61K 2039/55527 (2013.01 - EP); A61K 2039/55533 (2013.01 - EP); A61K 2039/57 (2013.01 - EP); C12N 2501/23 (2013.01 - EP)
C-Set (source: EP)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 02089832 A2 20021114; WO 02089832 A3 20040325; CA 2447360 A1 20021114; CN 1531440 A 20040922; EP 1418936 A2 20040519; JP 2004536800 A 20041209
DOCDB simple family (application)
DK 0200295 W 20020507; CA 2447360 A 20020507; CN 02813325 A 20020507; EP 02724144 A 20020507; JP 2002586964 A 20020507